Proteostasis Therapeutics Inc (NASDAQ:PTI) was the recipient of a significant decline in short interest during the month of December. As of December 29th, there was short interest totalling 919,447 shares, a decline of 52.3% from the December 15th total of 1,927,302 shares. Currently, 4.2% of the shares of the stock are short sold. Based on an average trading volume of 1,134,827 shares, the short-interest ratio is currently 0.8 days.
Proteostasis Therapeutics (PTI) opened at $5.04 on Friday. The company has a market capitalization of $166.89 and a P/E ratio of -2.28. Proteostasis Therapeutics has a 12 month low of $1.41 and a 12 month high of $16.67.
Proteostasis Therapeutics (NASDAQ:PTI) last posted its quarterly earnings data on Tuesday, November 14th. The company reported ($0.56) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.72) by $0.16. The company had revenue of $1.55 million for the quarter, compared to analyst estimates of $1.38 million. Proteostasis Therapeutics had a negative return on equity of 93.15% and a negative net margin of 712.49%. equities research analysts predict that Proteostasis Therapeutics will post -2.47 EPS for the current fiscal year.
In other news, Director Franklin M. Berger purchased 60,000 shares of Proteostasis Therapeutics stock in a transaction dated Monday, December 18th. The shares were bought at an average cost of $5.00 per share, for a total transaction of $300,000.00. Following the completion of the acquisition, the director now owns 266,162 shares in the company, valued at approximately $1,330,810. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Meenu Chhabra purchased 40,000 shares of Proteostasis Therapeutics stock in a transaction dated Monday, December 18th. The shares were purchased at an average price of $5.00 per share, for a total transaction of $200,000.00. Following the completion of the acquisition, the insider now owns 50,218 shares of the company’s stock, valued at approximately $251,090. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 2,100,000 shares of company stock worth $10,500,000. Company insiders own 17.40% of the company’s stock.
Institutional investors have recently bought and sold shares of the stock. Susquehanna International Group LLP acquired a new position in shares of Proteostasis Therapeutics in the second quarter worth approximately $254,000. FMR LLC lifted its stake in shares of Proteostasis Therapeutics by 2.3% in the second quarter. FMR LLC now owns 2,944,915 shares of the company’s stock worth $13,782,000 after acquiring an additional 66,111 shares during the period. Bain Capital Public Equity Management LLC acquired a new position in shares of Proteostasis Therapeutics in the second quarter worth approximately $1,233,000. Dimensional Fund Advisors LP acquired a new position in shares of Proteostasis Therapeutics in the second quarter worth approximately $296,000. Finally, Sabby Management LLC lifted its stake in shares of Proteostasis Therapeutics by 109.6% in the second quarter. Sabby Management LLC now owns 125,151 shares of the company’s stock worth $586,000 after acquiring an additional 65,451 shares during the period. 51.80% of the stock is currently owned by institutional investors.
PTI has been the topic of several research reports. Robert W. Baird boosted their price target on Proteostasis Therapeutics from $13.00 to $25.00 and gave the stock an “outperform” rating in a report on Tuesday, December 12th. Leerink Swann boosted their price target on Proteostasis Therapeutics from $6.00 to $8.00 in a report on Tuesday, December 12th. Zacks Investment Research cut Proteostasis Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 18th. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Proteostasis Therapeutics in a report on Tuesday, December 19th. Finally, ValuEngine cut Proteostasis Therapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Two investment analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. Proteostasis Therapeutics has a consensus rating of “Hold” and a consensus target price of $16.00.
ILLEGAL ACTIVITY NOTICE: “Proteostasis Therapeutics Inc (PTI) Short Interest Down 52.3% in December” was first published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/01/14/proteostasis-therapeutics-inc-pti-short-interest-down-52-3-in-december.html.
Proteostasis Therapeutics Company Profile
Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.
Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.